Navigation Links
Wayne State study finds soybean compounds enhances effects of cancer radiotherapy

Detroit - A Wayne State University researcher has shown that compounds found in soybeans can make radiation treatment of lung cancer tumors more effective while helping to preserve normal tissue.

A team led by Gilda Hillman, Ph.D., professor of radiation oncology at Wayne State University's School of Medicine and the Barbara Ann Karmanos Cancer Institute, had shown previously that soy isoflavones, a natural, nontoxic component of soybeans, increase the ability of radiation to kill cancer cells in prostate tumors by blocking DNA repair mechanisms and molecular survival pathways, which are turned on by the cancer cells to survive the damage radiation causes.

At the same time, isoflavones act to reduce damage caused by radiation to surrounding cells of normal, noncancerous tissue. This was shown in a clinical trial conducted at WSU and Karmanos for prostate cancer patients treated with radiotherapy and soy tablets.

In results published in the journal Nutrition and Cancer in 2010, those patients experienced reduced radiation toxicity to surrounding organs; fewer problems with incontinence and diarrhea; and better sexual organ function. Hillman's preclinical studies in the prostate tumor model led to the design of that clinical trial.

Soy isoflavones can make cancer cells more vulnerable to ionizing radiation by inhibiting survival pathways that are activated by radiation in cancer cells but not in normal cells. In normal tissues, soy isoflavones also can act as antioxidants, protecting those tissues from radiation-induced toxicity.

During the past year, Hillman's team achieved similar results in non-small cell lung cancer cells in vitro. She recently received a two-year, $347,000 grant from the National Cancer Institute, part of the National Institutes of Health, to investigate whether those results also proved true for non-small cell lung tumors in mice, and has found that they do. Her findings, which she called "substantial" and "very promising," appear in the November 2011 edition of the journal Radiotherapy and Oncology.

Hillman emphasized that soy supplements alone are not a substitute for conventional cancer treatment, and that doses of soy isoflavones must be medically administered in combination with conventional cancer treatments to have the desired effects.

"Preliminary studies indicate that soy could cause radioprotection," she said. "It is important to show what is happening in the lung tissue."

The next step, she said, is to evaluate the effects of soy isoflavones in mouse lung tumor models to determine the conditions that will maximize the tumor-killing and normal tissue-protecting effects during radiation therapy.

"If we succeed in addressing preclinical issues in the mouse lung cancer model showing the benefits of this combined treatment, we could design clinical protocols for non-small cell lung cancer to improve the radiotherapy of lung cancer," Hillman said. "We also could improve the secondary effects of radiation, for example, improving the level of breathing in the lungs."

Once protocols are developed, she said, clinicians can begin using soy isoflavones combined with radiation therapy in humans, a process they believe will yield both therapeutic and economic benefits.

"In contrast to drugs, soy is very, very safe," Hillman said. "It's also readily available, and it's cheap.

"The excitement here is that if we can protect the normal tissue from radiation effects and improve the quality of life for patients who receive radiation therapy, we will have achieved an important goal."


Contact: Julie O'Connor
Wayne State University - Office of the Vice President for Research

Related biology news :

1. Genomatix gives a hand in the analysis of Wayne States sequencing projects
2. NextCAT Inc. secures $250,000 to commercialize biodiesel technology developed at Wayne State
3. NextCAT secures license agreement for advanced biofuel technology from Wayne State
4. Soy increases effectiveness of radiation at killing lung cancer, Wayne State study shows
5. Wayne State University chosen as Michigans sole participant in EcoCAR 2
6. Wayne State to study the role of vitamin D in African-Americans with high blood pressure
7. Wayne State researcher discovers antibiotic useful for localized treatment of bone wear
8. Wayne State start-up company NextCAT awarded nearly $500,000 from NSF for Phase II SBIR
9. EPA grants help Wayne State researchers stave off Great Lakes environmental invaders
10. Wayne State announces license agreement for breakthrough approaches to vision restoration
11. Better CMT outcome measurement is Wayne State University physicians goal
Post Your Comments:
(Date:11/20/2015)... , November 20, 2015 ... company focused on the growing mobile commerce market and ... Gino Pereira , was recently interviewed on ... will air on this weekend on Bloomberg Europe ... America . --> NXTD ) ("NXT-ID" or ...
(Date:11/17/2015)... 17, 2015 Paris from ... --> Paris from 17 th until ... biometrics innovation leader, has invented the first combined scanner in ... same scanning surface. Until now two different scanners were required: ... can capture both on the same surface. This innovation ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... Harvard Apparatus Regenerative Technology, Inc. (HART) ... bioengineered organ implants for life-threatening conditions, today announced ... Stock Market that it has regained compliance with ... that as a result of the closing bid ... per share for more than ten consecutive business ...
(Date:11/30/2015)... 30, 2015  Champions Oncology, Inc. (CSBR), engaged in ... personalize the development and use of oncology drugs, today ... will be presenting at the LD MICRO Investor Conference ... Time (PST).  The conference, held at the Luxe Sunset ... , will feature 200 small/micro-cap companies and is ...
(Date:11/30/2015)... -- Aytu BioScience, Inc. (OTCQB: AYTU), a commercial-stage specialty healthcare ... at two upcoming investor conferences. Aytu is scheduled to ... to be held December 3, 2015, and at LD ... 2 nd & 3 rd , 2015 in ... via webcast. Josh Disbrow , Chief Executive ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... MarkLogic, the Enterprise NoSQL database platform provider, creating a seamless approach to ... Content Intelligence capabilities provide a robust set of semantic tools which create ...
Breaking Biology Technology: